BPCE
NTLA icon

Bank Pictet & Cie (Europe)’s Intellia Therapeutics NTLA Stock Holding History

Bank Pictet & Cie (Europe)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,039
Closed -$282K – 171
2022
Q3 		$282K Buy
+5,039
New +$313K 0.01% 147
2022
Q1 		– Sell
-2,308
Closed -$273K – 183
2021
Q4 		$273K Buy
+2,308
New +$289K 0.01% 153

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bank Pictet & Cie (Europe)'s NTLA Position: Q4 2022 in Review

Bank Pictet & Cie (Europe) sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 5,039 shares — an estimated $282K sold.

Bank Pictet & Cie (Europe) first reported a position in NTLA in Q4 2021 and held it in 2 quarters. The position peaked at $282K in Q3 2022. 304 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Bank Pictet & Cie (Europe) reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Bank Pictet & Cie (Europe) sold 5,039 Intellia Therapeutics shares in Q4 2022, an estimated $282K.
  • Bank Pictet & Cie (Europe) first reported a position in Intellia Therapeutics in Q4 2021 and held it in 2 quarters.
  • Bank Pictet & Cie (Europe)'s Intellia Therapeutics position peaked at $282K in Q3 2022.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Bank Pictet & Cie (Europe)'s 13F filing for Q4 2022, filed 8 Feb 2023.